摘要
目的 评估舌下含服粉尘螨疫苗免疫治疗（sublingual immunotherapy,SLIT）对我国西南地区粉尘螨过敏的不同年龄段变应性鼻炎（allergic rhinitis,AR）患者间的疗效及安全性差异。方法 选择2014年1月至2015年1月在第三军医大学西南医院耳鼻咽喉科门诊部的AR患者92例。将AR患者分成2组,其中5~18岁的患者为儿童及青少年组（42例）,〉18~57岁的患者为成人组（50例）。分别分析2组AR患者在治疗前,治疗后3、6个月以及1年的症状评分,同时对治疗过程中发生的不良反应事件进行记录。结果 2组AR患者在SLIT治疗前,治疗后3、6个月以及1年的疗效评分均呈递减趋势,其中A组评分分别为（8.53±1.31）、（5.82±1.05）、（2.14±1.17）、（1.03±0.88）,B组评分分别为（8.64±1.35）、（6.05±1.33）、（2.64±1.35）、（1.16±0.89）。2组AR患者在SLIT治疗后3、6个月以及1年的症状评分与治疗前症状评分的组内比较差异均有统计学意义（P〈0.05）,而2组相同治疗时间的组间比较差异均无统计学意义（P〉0.05）。2组在SLIT治疗的前3个月均未发生重度不良反应事件,但是共发生10例轻度不良反应事件,儿童及青少年组AR患者不良反应事件的发生率（19.05%,8/42）高于成人组（4.00%,2/50,P〈0.05）。2组AR患者在SLIT治疗时间超过3个月后,均未再发生不良反应事件。结论 SLIT对于不同年龄段的AR患者均有可靠的疗效和安全性,但在开始治疗的前3个月儿童及青少年段的AR患者相对容易发生轻度不良反应事件。SLIT适合于治疗不同年龄段的AR患者。
Objective To evaluate the differences on the efficacy and safety of sublingual immunotherapy （SLIT） of vaccine for dust mite allergies on the patients with allergic rhinitis （AR） of different ages living in the Southwest China. Methods A total of 92 AR patients living in Southwest China who were sensitized to house dust mites and given SLIT for more than 1 year were followed up through telephone and E- mail during January 2014 to January 2015. The patients were divided into 2 groups： child and adolescent groups （5 to 18 years old, n =42） and adult group （19 to 57 years old, n =50）. The total nasal symptom scores （TNSS） and adverse events were recorded and analyzed between the 2 groups before, and in 3 and 6 months and 1 year after treatment. Results The TNSS was in a declining trend in the both 2 groups. Before and in 3 and 6 months and 1 year after SLIT treatment, the average score was 8.53 ± 1.31, 5.82 ± 1.05,2. 14 ± 1.17 and 1.03 ± 0.88, respectively in the child and adolescent group, and 8.64 ±1.35, 6.05 ±1.33, 2.64 ± 1.35 and 1.16 ± 0.89 separately in the adult group. Significant differences were seen in the TNSS scores in the 2 groups before and after the treatment （ P 〈 0.05 ） , but not between the 2 groups at the same time points （ P 〉 0.05 ）. There were no sever adverse events occurred in both groups during the first 3 months of SLIT, but 10 cases mild adverse events were observed, with 8 cases from the child and adolescent group （8/42） and 2 cases out of the adult group （2/50, P 〈 0.05 ）. Both groups had no adverse events occurred after 3 months＇ treatment. Conclusion SLIT of vaccine for dust mite allergies shows reliable efficacy and safety in the treatment of AR patients at different ages. But children and adolescents might be prone to mild adverse events in the first 3 months of treatment. SLIT is suitable for AR patients of different ages.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2016年第18期2091-2095,共5页
Journal of Third Military Medical University
关键词
变应性鼻炎
特异性免疫治疗
投药
舌下
粉尘螨
allergic rhinitis
specific immunotherapy
age
efficacy
safety
dust mites
